These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

146 related items for PubMed ID: 2736154

  • 1. Cross-over study of fat-corrected forearm mineral content during nandrolone decanoate therapy for osteoporosis.
    Need AG, Horowitz M, Walker CJ, Chatterton BE, Chapman IC, Nordin BE.
    Bone; 1989; 10(1):3-6. PubMed ID: 2736154
    [Abstract] [Full Text] [Related]

  • 2. Effects of nandrolone therapy on forearm bone mineral content in osteoporosis.
    Need AG, Horowitz M, Morris HA, Walker CJ, Nordin BE.
    Clin Orthop Relat Res; 1987 Dec; (225):273-8. PubMed ID: 3677513
    [Abstract] [Full Text] [Related]

  • 3. Treatment of postmenopausal osteoporosis: is the anabolic steroid nandrolone decanoate a candidate?
    Johansen JS, Hassager C, Pødenphant J, Riis BJ, Hartwell D, Thomsen K, Christiansen C.
    Bone Miner; 1989 Apr; 6(1):77-86. PubMed ID: 2665884
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Effects of nandrolone decanoate on forearm mineral density and calcium metabolism in osteoporotic postmenopausal women.
    Need AG, Morris HA, Hartley TF, Horowitz M, Nordin BE.
    Calcif Tissue Int; 1987 Jul; 41(1):7-10. PubMed ID: 3113703
    [Abstract] [Full Text] [Related]

  • 7. Effects of nandrolone decanoate and antiresorptive therapy on vertebral density in osteoporotic postmenopausal women.
    Need AG, Horowitz M, Bridges A, Morris HA, Nordin BE.
    Arch Intern Med; 1989 Jan; 149(1):57-60. PubMed ID: 2912415
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Bone mineral content, cortical thickness and fracture rate in osteoporotic women after withdrawal of treatment with nandrolone decanoate, 1-alpha hydroxyvitamin D3, or intermittent calcium infusions.
    Geusens P, Dequeker J, Verstraeten A, Nijs J, Van Holsbeeck M.
    Maturitas; 1986 Dec; 8(4):281-9. PubMed ID: 3574141
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Long-term effect of nandrolone decanoate, 1 alpha-hydroxyvitamin D3 or intermittent calcium infusion therapy on bone mineral content, bone remodeling and fracture rate in symptomatic osteoporosis: a double-blind controlled study.
    Geusens P, Dequeker J.
    Bone Miner; 1986 Sep; 1(4):347-57. PubMed ID: 3333018
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [Prophylaxis and treatment of osteoporosis].
    Kopera H.
    Klin Wochenschr; 1989 May 15; 67(10):557-8. PubMed ID: 2739351
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.